The modern trends in diagnosis and treatment of primary operable breast cancer
https://doi.org/10.17650/1994-4098-2018-14-4-24-34
Abstract
The article considers the modern methods of diagnosis and treatment of primary operable breast cancer depending on molecular biological profile of the tumor.
About the Author
N. I. Mekhtieva
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
Russian Federation
Russian Federation
24 Kashirskoe Shosse, Moscow 115478
References
1. Davydov M.I., Aksel E.M. Cancer epidemiology 2015. Evraziyskiy onkologicheskiy zhurnal = Eurasian Journal of Oncology 2017;2: 298–318. (In Russ.).
2. Goldhirsch A., Winer E.P., Coates A.S. et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 2013;24(9):2206–23. PMID: 23917950. DOI: 10.1093/annonc/mdt303.
3. Park S., Park H.S., Kim S.I. The impact of a focally positive resection margin on the local control in patients treated with breast-conserving therapy. J Clin Oncol 2011;41(5):600–8. PMID: 21355001. DOI: 10.1093/jjco/hyr018.
4. Gobardhan P.D., de Wall L.L., van der Laan L. et al. The role of radioactive iodine-125 seed localization in breastconserving therapy following neoadjuvant chemotherapy. Ann Oncol 2013;24(3):668–73. PMID: 23139261. DOI: 10.1093/annonc/mds475.
5. Prat A., Perou C.M. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2010;5:5–23.
6. Cancello G., Maisonneuve P., Rotmensz N. et al. Progesterone receptor loss identifies Luminal B breast cancer subgroups at higher risk of relapse. Ann Oncol 2013;24(3):661–8. PMID: 23022996. DOI: 10.1093/annonc/mds430.
7. Ognerubov N.A. Clinical significance of biological variants of breast cancer. Molekulyarnaya meditsina = Molecular Medicine 2015;2:31–5. (In Russ.).
8. Hugh J., Hanson J., Cheang M.C. et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 Trial. J Clin Oncol 2009;27(8):1168–76. PMID: 19204205. DOI: 10.1200/JCO.2008.18.1024.
9. Cheang M.C., Chia S.K., Voduc D. et al. Ki67 Index, HER2 Status, and prognosis of patients with luminal B breast Cancer. J Natl Cancer Inst 2009;101(10):736–50. PMID: 19436038. DOI: 10.1093/jnci/djp082.
10. Marcom P.K., Isaacs C., Harris L. et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007;102(1):43–9. PMID: 16897431. DOI: 10.1007/s10549-006-9307-8.
11. Cui X., Schiff R., Arpino G. et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005;23(30):7721–35. PMID: 16234531. DOI: 10.1200/JCO.2005.09.004.
12. Rakha E.A., El-Sayed M.E., Green A.R. et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007;25(30):4772–8. PMID: 17876012. DOI: 10.1200/JCO.2007.12.2747.
13. Creighton C.J., Kent Osborne C., van de Vijver M.J. et al. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2009;114:287–99.
14. Ades F., Zardavas D., Bozovic-Spasojevic I. et al. Luminal-B breast cancer: molecular characteristics, treatment, and outlooks. J Clin Oncol (Rus) 2014;8(4):245. (In Russ.).
15. Maisonneuve P., Disalvatore D., Rotmensz N. et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res 2014;16(3):R65. DOI: 10.1186/bcr3679.
16. Shestakov A.A., Sabirov A.H., Sadykova E.V. Evaluation of HER-2/NEU protein expression in breast cancer. Meditsinskaya nauka i obrazovanie Urala = Medical Science and Education in the Ural Region 2014;(1):142–5. (In Russ.).
17. Bose S. Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes. Аdv Anat Pathol 2015;22(5):306–13. DOI: 10.1097/PAP.0000000000000084.
18. Gonçalves A., Sabatier R., Charafe-Jauffret E. et al. Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives. Bull Cancer 2013;100(5):453–64. DOI: 10.1684/bdc.2013.1740.
19. Duffy M.J., McGowan P.M., Crown J. Targeted therapy for triple-negative breast cancer: where are we? Int J Cancer 2012;131(11):2471–7. DOI: 10.1002/ijc.27632.
20. Kolyadina I.V., Poddubnaya I.V., Trofimova O.P. Tumor biology or adjuvant systemic therapy: what determines the risk of stage 1 breast cancer recurrence? Sovremennaya onkologiya = Current Oncology 2014;16(4):24–8. (In Russ.).
21. Volchenko A.A., Chissov V.I., Zikiryakhodzhaev A.D. Choice of a reconstructive technique in comprehensive treatment of patients with breast cancer. Onkologiya. Zhurnal imeni P.A. Gertsena = P.A. Herzen Journal of Oncology 2014;(1):3–9. (In Russ.).
22. Zubareva I.A. Value of ultrasound-guided percutaneous fineneedle biopsy in the diagnosis of breast cancer in South-Western regions of Bryansk region. Sonoace Ultrasound 2010;(20):61–6. (In Russ.).
23. Guidroz J.A., Scott-Conner C.E.H., Weiget R.J. Management of pregnant women with breast cancer. J Surg Oncol 2011;103(4):337–40. PMID: 21337568. DOI: 10.1002/jso.21673.
24. Bullier B., MacGrogan G., Bonnefoi H. et al. Imaging features of sporadic breast cancer in women under 40 years old. Eur Radiol 2013;23(12):3237–45. PMID: 23918218. DOI: 10.1007/s00330-013-2966-z.
25. Olivas-Maguregui S., Villasenor-Navarro Y., Ferrari-Carballo T. et al. Importance of the preoperative evaluation of multifocal and multicentric breast cancer with magnetic resonance imaging in women with dense parenchyma. Rev Invest Clin 2008;60(5):382–9. PMID: 19227435.
26. Trufanov G.E., Ryazanov V.V., Fokin V.A. et al. Breast sonoelastography: methodological aspects and differential diagnosis of tumors. Byulleten FTSKE = Bulletin of Almazov Federal Heart, Blood, and Endocrinology Centre 2013;(2):45–53. (In Russ.).
27. Busko E.A., Mishchenko A.V., Semiglazov V.V. Determining the cutoff value of strain ratio measured by sonoelastography in differential diagnosis of benign and malignant breast tumors. Kremlevskaya meditsina. Klinicheskiy vestnik = Kremlin medicine. Clinical Bulletin 2013;(1):112–3. (In Russ.).
28. Kabin Yu.V., Gromov A.I., Kapustin V.V. Shear wave elastography in the diagnosis of breast cancer: first experience. Ultrazvukovaya i funktsionalnaya diagnostika = Ultrasound and Functional Diagnostics 2013;(5):79–84.
29. Kanaev S.V., Novikov S.N., Krivorotko P.V. et al. Use of 99mTc sestamibi breast imaging for the diagnosis of breast cancer: methodological aspects. Voprosy onkologii = Problems in Oncology 2012;58(6):768–72. (In Russ.).
30. Krivorotko P.V. Diagnostic value of mammography and mammoscintigraphy in multifocal breast cancer. Voprosy onkologii = Problems in Oncology 2013;59(1):59–64. (In Russ.).
31. Pallone M.J., Poplack S.P., Barth R.J., Paulsen K.D. Combining supine MRI and 3D optical scanning for improved surgical planning of breast conserving sugeries. Conference on Medical Imaging 2012: Image-Guided Procedures, Robotic Interventions, and Modeling, San Diego, California, 5–7 February, 2012. DOI: doi.org/10.1117/12.912803.
32. Soares F., Janela F., Pereira M. et al. 3D lacunarity in multifractal analysis of breast tumor lesions in dynamic contrast-enhanced magnetic resonance imaging. IEEE Trans Image Process 2013;22 (11–12):4422–35.
33. Kalinyak Judith E., Berg Wendie A., Schilling K. et al. Breast cancer detection using high-resolution breast PET or PET/CT. Eur J Nucl Med Mol Imag 2014;41(2):260–75. PMID: 24085500. DOI: 10.1007/s00259-013-2553-1.
34. Schilling K., Narayanan D., Kalinyak J.E. et al. Positron emission mammography in breast cancer presurgical planning: Comparisons with magnetic resonance imaging. Eur J Nucl Med Mol Imag 2011;38(1):23–6.
35. Vladimirova A.V., Novik V.I., Krasilnikova L.A. et al. Efficiency of cytological examination in the diagnosis of breast tumors. Voprosy onkologii = Problems in Oncology 2015;61(4):614–8. (In Russ.).
36. Yarmolyuk A.L., Polovinkin A.A., Gladysheva O.G. Ultrasound-guided percutaneous fine-needle aspiration biopsy in the diagnosis of breast cancer. Targeted therapy in oncology. Proceedings of the Russian Research Conference with International Participation, Barnaul, 19–20 June, 2014. P. 101. (In Russ.).
37. Tuttle T.M., Rueth N.M., Abbott A., Virnig B.A. Trends in the local treatment of breast cancer: Should we be worried? J Surg Oncol 2011;103(4):313–6. PMID: 21337564. DOI: 10.1002/jso.21699.
38. Voogd A.C., van Oost F.J., Rutgers E.J. et al. Long term prognosis of patients with local recurrence after conservative surgery and radiotherapy for early breast cancer. Eur J Cancer 2005;41(17):2637–44. PMID: 16115758. DOI: 10.1016/j.ejca.2005.04.040.
39. Heuts E.M., van der Ent F.W.C., Hulsewe K.W.E. et al. Incidence of axillary recurrence in 344 sentinel node negative breast cancer patients after intermediate follow-up. A prospective study into accuracy of sentinel node biopsy in breast cancer patients. Acta Chir Belg 2007;107(3):279–83. PMID: 17685253.
40. Takei H., Suemasu K., Kurosumi M. et al. Recurrence after sentinel lymph node biopsi with or without axillary lymph node dissection in patients with breast cancer. Selec Pap Saitama Cancer Cent 2007;29:16–24.
41. Giuliano A.E., Hunt K.K., Ballman K.V. et al. Axillary dissection versus no axillary dissection in women with invasive breast cancer and sentinel node metastasis. JAMA 2011;305:569–75.
42. Galimberti V., Cole B.F., Zurrida S. et al. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): a phase 3 randomised controlled trial. Lancet Oncol 2013;14:297–305.
43. Provenzano E., Brown J.P., Pinder S.E. Pathological controversies in breast cancer: classification of ductal carcinoma in situ, sentinel lymph nodes and low volume metastatic disease and reporting of neoadjuvant chemotherapy specimens. Clin Oncol (R Coll Radiol) 2013;25(2):80–92. DOI: 10.1016/j.clon.2012.10.008.
44. Borovikov A.M. Breast reconstruction after mastectomy. Tver: “Gubernskaya meditsina” LLC, 2000. P. 5. (In Russ.).
45. Sobolevskiy V.A., Egorov Yu.S., Krokhina O.V. Options for reconstructive surgery in patients with breast cancer. Vmeste protiv raka = Together Against Cancer 2007;(1–2):10–4. (In Russ.).
46. Trabulsy P.P., Anthony J.P., Mathes S.J. Changing trends in post mastectomy breast reconstruction: A 13-year experience. Plast Reconstr Surg 1994;93(7):1418–27.
47. Caruso F., Ferrara M., Castiglione G. et al. Nipple sparing subcutaneous mastectomy: sixty-six months follow-up. Eur J Surg Oncol 2006;32(9):937.
48. Sacchini V.S., de Alcantara Filho P., Capko D. et al. Nipple-sparing mastectomy for breast cancer and risk-reducing surgery: the Memorial Sloan-Kettering Cancer Center experience. Ann Surg Oncol 2011;18(11):3117–22.
49. Komorowski A.L., Zanini V., Regolo L. et al. Necrotic complications after nippleand areolasparing mastectomy. World J Surg 2006;30(8):1410. PMID: 16850148. DOI: 10.1007/s00268-005-0650-4.
50. Semiglazov V.V., Donskikh R.V., Semiglazova T.Yu. et al. Taxotere in neoadjuvant treatment of breast cancer. Voprosy onkologii = Problems in Oncology 2011;57(5):645–50. (In Russ.).
51. Shapoval E.V. Vinorelbincyclophosphamide-5-fluorouracil in neoadjuvant treatment of T1–2N0–1M0 breast cancer. Sovremennye tekhnologii v meditsine = Modern Technologies in Medicine 2011;1:24–8. (In Russ.).
52. Untch M., Konecny G.E., Paepke S., von Minckwitz G. Current and future role of neoadjuvant therapy for breast cancer. Breast 2014;23(5):526–37. DOI: 10.1016/j.breast.2014.06.004.
53. Markosyan S.I., Lazarev A.F., Churilova L.A. et al. Outcomes of combination treatment with neoadjuvant chemotherapy in patients with breast cancer. High technologies in oncology. Proceedings of the Russian Research Conference with International Participation. Barnaul, 26–27 June, 2012. P. 170, 171. (In Russ.).
54. Kolyadina I.V., Poddubnaya I.V., Frank G.A. et al. Evolution of adjuvant therapy for early-stage breast cancer (a multicenter study). Sovremennaya onkologiya = Current Oncology 2012;14(1):16–20. (In Russ.).
55. Joerger M., Thürlimann B. Chemotherapy regimens in early breast cancer: major controversies and future outlook. Expert Rev Anticancer Ther 2013;13(2):165–78. DOI: 10.1586/era.12.172.
56. Sonnenblick A., Fumagalli D., Azim H.A.Jr. et al. New strategies in breast cancer: the significance of molecular subtypes in systemic adjuvant treatment for small T1a,bN0M0 tumors. Clin Cancer Res 2014;20(24):6242–6. DOI: 10.1158/10780432.CCR-14-1086.
57. Lehmann B.D., Pietenpol J.A. Indentification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol 2014;232(2):142–50. PMID: 24114677. DOI: 10.1002/path.4280.
58. Ivanova F.G., Nikolaeva T.N., Gorbunova V.A. Evaluating the efficacy and toxicity of a standard chemotherapy regimen for breast cancer. Sibirskiy onkologicheskiy zhurnal = Siberian Journal of Oncology 2009;(5):56–9. (In Russ.).
59. Semiglazov V.F. Breast cancer: a multidisciplinary approach to treatment. Prakticheskaya onkologiya = Practical Oncology 2015;16(2):49–54. (In Russ.).
60. Martin M., Ruiz A., Borrego R. et al. Fluorouracil, doxorubicin and cyclophosphamide (FAC) vs FAC, and then weekly paclitaxel as an adjuvant therapy for high-risk breast cancer without lymph node injury: the results of a GEICAM/2003-2 study. J Clin Oncol (Rus) 2013;7(3):254–5. (In Russ.).
61. Kolyadina I.V., Poddubnaya I.V. Role of Taxotere in adjuvant therapy for earlystage breast cancer. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System 2013;(3–4):54–9. (In Russ.).
62. Jacquemier J., Boher J.M., Roche H. et al. Protein expression, survival and docetaxel benefit in nodal-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomised trial. Breast Cancer Res 2011;13(6):R109. DOI: 10.1186/bcr3051.
63. Artamonova E.V. Docetaxel in adjuvant therapy for early-stage lymph nodenegative (N0) breast cancer. Sovremennaya onkologiya = Current Oncology 2012;14(1):10–4. (In Russ.).
64. Borisova E.I., Gutorov S.L., Vorontsov A.Yu. Endocrine therapy for breast cancer: optimal regimen and overcoming the resistance. Farmateka = Pharmateca 2012;(18):56–60. (In Russ.).
65. Ivanova O.A., Zhiltsova E.K., Barash N.Yu. et al. Is low-dose tamoxifen effective for breast carcinoma in situ? Voprosy onkologii = Problems in Oncology 2011;57(5):601–3. (In Russ.).
66. Huang B., Omoto Y., Iwase H. et al. Differential expression of estrogen receptor α, β1 and β2 in lobular and ductal breast cancer. Proc Nat Acad Sci USA 2014;111(5):1933–8.
67. Viale G., Regan M.M., Maiorano E. et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007;25:3846–52.
68. Dowsett M., Lopez-Knowles E., Sidhu K. et al. Comparison of PAM50 risk of recurrence (ROR) score with Oncotype DX and IHC4 for predicting residual risk of RFS and distant-(D)RFS after endocrine therapy: a transATAC study. Cancer Res 2011;71(3):4–5.
69. Semiglazov V.F., Manikhas A.G., Semiglazov V.V. et al. Long-term outcomes of adjuvant endocrine therapy for hormone receptor-positive breast cancer. Voprosy onkologii = Problems in Oncology 2011;57(5):567–77. (In Russ.).
70. Semiglazov V.F., Dashyan G.A., Semiglazov V.V. Endocrine therapy for breast cancer: resistance overcoming. Effektivnaya farmakoterapiya = Effective pharmacotherapy 2015;(10):32–42. (In Russ.).
71. Portnoy S.M., Shendrikova T.A. Ten-year adjuvant hormone therapy for breast cancer: pros and cons. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System 2013;(3–4):50–3. (In Russ.).
72. Malaguti P., Vari S., Cognetti F. The mammalian target of rapamycin ingibitors in breast cancer. Anticancer Res 2013;33(1):21–8. PMID: 23267124.
73. Kolyadina I.V., Makarenko N.P., Poddubnaya I.V. Everolimus: new outlooks for therapy of advanced hormone receptor-positive breast cancer. Sovremennaya onkologiya = Current Oncology 2012;4(4):16–20. (In Russ.).
74. Semiglazova T.Yu., Semiglazov V.V., Filatova L.V. et al. New approach to overcome resistance to hormone therapy in breast cancer. Farmateka = Pharmateca 2012;(18):50–5. (In Russ.).
75. Tookman L., Roylance R. New drugs for breast cancer. Brit Med Bull 2010;96:111–29. PMID: 20870669. DOI: 10.1093/bmb/ldq029.
76. Prat A., Pineda E., Adamo B. et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast 2015;24(suppl 2):S26–35. DOI: 10.1016/j.breast.2015.07.008.
77. Lysenko O.V., Mazharova E.S., Korobkova T.N. Short-term treatment outcomes in patients with HERpositive breast cancer. Tyumenskiy meditsinsky zhurnal = Tyumen Medical Journal 2012;(4):59–61. (In Russ.).
78. Semiglazov V.F., Paltuev R.M., Semiglazov V.V. et al. Adjuvant treatment of HER2-positive breast cancer. Russkiy meditsinskiy zhurnal = Russian Medical Journal 2013;(2):49–51. (In Russ.).
79. Sukhodolskaya Yu.V., Petrova V.D. Herceptin in adjuvant treatment of breast cancer patients in outpatient departments. New Methods in Oncology Practice 2013:164–5. (In Russ.).
80. Zhukova L.G., Lichinitser M.R. Adjuvant therapy with trastuzumab for early-stage breast cancer: 12 or 24 months (according to ESMO, Vienna, October, 2012). Farmateka = Pharmateca 2012;(18): 69–70. (In Russ.).
81. Semiglazov V.F., Semiglazov V.V. Four aspects of adjuvant targeted therapy for HER2-positive breast cancer. Farmateka = Pharmateca 2013;(8):10–4. (In Russ.).
82. Artamonova E.V., Manzyuk L.V. HER2-positive metastatic breast cancer: new treatment options. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System 2013;(3–4):60–6. (In Russ.).
83. Semiglazov V.F., Semiglazov T.Yu., Bozhok T.A. et al. Neoadjuvant targeted therapy for breast cancer. Effektivnaya farmakoterapiya = Effective pharmacotherapy 2013;(6):12–6. (In Russ.).
84. Sakaeva D.D. Earlystage breast cancer. Various aspects of combination treatment. New approaches to neoadjuvant therapy of early-stage HER2-positive breast cancer. Zlokachestvennye opukholi = Malignant Tumors 2013;(1):38–40. (In Russ.).
85. Bolotina L.V., Kramskaya L.V., Smirnova I.A. et al. Combination therapy with lapatinib for HER2-positive advanced breast cancer: case reports. Sovremennaya onkologiya = Current Oncology 2012;14(1):21–2. (In Russ.).
86. Fisher Ch.M., Rabinovitch R. Achievements of radiation therapy for early-stage invasive breast cancer. J Clin Oncol (Rus) 2014;8(4):248. (In Russ.).
87. Beitsch P.D., Shaitelman S.F., Vicini F.A. Accelereted partial breast irradiation. J Surg Oncol 2011;103(4):362–8. DOI: 10.1002/jso.21785.
88. Trofimova O.P., Kolyadina I.V., Avramidi S.F. et al. Preliminary results of accelerated partial breast irradiation in comprehensive organ-sparing treatment of patients with early-stage breast cancer. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System; 2013;(1–2):28–34. (In Russ.).
89. Efimkina Yu.V., Gladilina I.A., Nechushkin M.I. Hypofractionated radiation therapy after organ-sparing surgery for stage I–IIA breast cancer. Opukholi zhenskoy reproduktivnoy sistemy = Tumors of Female Reproductive System; 2010;(2):26–30. (In Russ.).
90. Olivotto I.A., Whelan T.J., Parpia S. et al. Cosmetic results and radiation reactions after accelerated partial breast irradiation using threedimensional conformal external beam radiation therapy: interim results of a randomized study RAPID. J Clin Oncol (Rus) 2013;7(4):323. (In Russ.).
91. Orecchia R., Leonardi M.C. Partial breast irradiation: targeting volume or breast molecular subtypes? Breast 2013;22(suppl 2):S137– 40. DOI: 10.1016/j.breast.2013.07.025.
92. Kaidar-Person O., Lai C., Kuten A., Belkacemi Y. “The Infinite Maze” of breast cancer, signaling pathways and radioresistance. Breast 2013;22(4):411–8. DOI: 10.1016/j.breast.2013.04.003.
Review
For citations:
Mekhtieva N.I. The modern trends in diagnosis and treatment of primary operable breast cancer. Tumors of female reproductive system. 2018;14(4):24-34. (In Russ.) https://doi.org/10.17650/1994-4098-2018-14-4-24-34
Views:
1077
Email this article 